Supraaortic arteries: contrast material dose reduction at 3.0-T high-spatial-resolution MR angiography--feasibility study

Effect of Contrast Agent Dose Reduction on Vascular Enhancement and Image Quality in Thoracoabdominal Dynamic 3-Dimensional Magnetic Resonance Angiography: A Systematic Intraindividual Analysis in Pigs

OBJECTIVE

High spatial and temporal resolution contrast-enhanced magnetic resonance angiography (MRA) with gadolinium-based contrast agents (GBCAs) at standard dose offers both detailed anatomic information on both arterial and venous vessels and hemodynamic characteristics. Several preclinical and clinical dynamic 3-dimensional (3D) MRA studies that focused on arterial vessels only proposed that high image quality may also be achieved with significantly reduced GBCA doses, calling into question the need to use standard doses. A systematic analysis of GBCA doses and resulting image quality for both arteries and veins has not yet been performed. The purpose of this study was therefore to systematically analyze dose-dependent vascular enhancements in dynamic 3D-MRA of the thoracoabdominal vasculature at 1.5 T in an animal model to determine the optimal contrast agent protocol for optimized vascular assessment.

MATERIALS AND METHODS

The vascular enhancement in thoracoabdominal dynamic 3D-MRA (time-resolved angiography with interleaved stochastic trajectories, TWIST at 1.5 T) was interindividually and intraindividually compared in 5 anesthetized Göttingen minipigs using gadobutrol at the standard dose (0.1 mmol/kg body weight, ie, 0.1 mL/kg) and at reduced doses (0.08, 0.06, 0.04, 0.02 mmol/kg) in a randomized order. All injections were performed at 2 mL/s followed by 20 mL saline. Images were quantitatively analyzed, measuring signal intensities in 5 regions that covered the passage of the GBCA through the body at different representative stages of circulation (pulmonary, arterial, and venous system). The evaluation of GBCA dose-dependent signal intensity changes in the different vascular regions was performed by linear regression analysis.The qualitative image analysis of dynamic 3D-MRA by 3 independent radiologists included the visibility of 25 arterial and venous vessel segments at different stages of GBCA passage. Possible quality losses were statistically tested by comparing image quality ratings at the reduced dose with that of the standard dose using Friedman test followed by Dunn post hoc test for multiple comparison. Significance was stated at P < 0.05.

RESULTS

Quantitative analysis revealed shorter time-to-peak intervals and bolus durations in line with decreasing GBCA dose and volume in all vessels. Although the peak signal was almost independent of the administered GBCA dose at the level of the pulmonary trunk, a linear signal decrease in the abdominal aorta ( r2 = 0.96), the renal arteries ( r2 = 0.99), the inferior vena cava ( r2 = 0.99), and the portal vein ( r2 = 0.97) was observed. Cumulative analysis of arterial segments revealed significantly lower image quality at doses below 40% of the standard dose, whereas in venous segments, significantly lower image quality was observed at doses below 60% of the standard dose.

CONCLUSIONS

In dynamic 3D-MRA at 1.5 T, dose reduction leads to a signal loss that is most pronounced in the venous system and results in significantly lower image quality according to the dose and vessels of interest. Careful dose reduction is thus required according to the specific diagnostic needs. For dynamic 3D-MRA of the arterial and venous system, GBCA doses of at least 60% of the standard dose up to the full dose are preferable, whereas 40% of the standard dose seems feasible if only the arterial system is to be imaged.

High-resolution three‑dimensional contrast‑enhanced magnetic resonance venography in children: comparison of gadofosveset trisodium with ferumoxytol

BACKGROUND

Gadofosveset is a gadolinium-based blood pool contrast agent that was approved by the United States Food and Drug Administration in 2008. Its unanticipated withdrawal from production in 2016 created a void in the blood pool agent inventory and highlighted the need for an alternative agent with comparable imaging properties.

OBJECTIVE

The purpose of our study is to compare the diagnostic image quality, vascular contrast-to-noise ratio (CNR) and temporal signal characteristics of gadofosveset trisodium and ferumoxytol at similar molar doses for high-resolution, three-dimensional (3-D) magnetic resonance (MR) venography in children.

MATERIALS AND METHODS

The medical records and imaging data sets of patients who underwent high-resolution 3-D gadofosveset-enhanced MR venography (GE-MRV) or ferumoxytol-enhanced MR venography (FE-MRV) were retrospectively reviewed. Two groups of 20 pediatric patients (age- and weight-matched with one patient common to both groups; age range: 2 days-15 years) who underwent high-resolution 3-D GE-MRV or FE-MRV at similar molar doses were identified and analyzed. Qualitative analysis of image quality and vessel definition was performed by two blinded pediatric radiologists. Interobserver agreement was assessed with the AC1 (first-order agreement coefficient) statistic. Signal-to-noise ratio (SNR) and CNR of the inferior vena cava and aorta were measured in the steady-state venous phase. Medical records were retrospectively reviewed for any adverse reactions associated with either contrast agent.

RESULTS

Measured SNR and CNR of the inferior vena cava were higher for FE-MRV than GE-MRV (P = 0.034 and P < 0.001, respectively). The overall image quality score and individual vessel scores of FE-MRV were equal to or greater than GE-MRV (P = 0.084), with good interobserver agreement (AC1 = 0.657). The venous signal on FE-MRV was stable over the longest interval measured (1 h, 13 min and 46 s), whereas venous signal on GE-MRV showed more variability and earlier loss of signal. No adverse reactions were noted in any patient with either contrast agent.

CONCLUSION

Ferumoxytol produces more uniform and stable enhancement throughout the entire venous circulation in children than gadofosveset, offering a wider time window for optimal image acquisition. FE-MRV offers a near-ideal approach to high-resolution venography in children at all levels of anatomical complexity.

Abdominal Magnetic Resonance Angiography

MR imaging hardware and software improvements have led to new applications for contrast-enhanced and noncontrast-enhanced magnetic resonance angiography in the abdomen and pelvis. Higher magnetic field strength MR imaging scanners have greater signal-to-noise ratio and contrast-to-noise ratio, which is used to improve spatial resolution or temporal resolution for these techniques. New noncontrast-enhanced sequences offer high-resolution magnetic resonance angiography without contrast and provide additional hemodynamic information. Magnetic resonance angiography is particularly well suited to imaging patients with chronic mesenteric ischemia, renal vascular disease, pelvic congestion syndrome, and vascular malformations.

Noninvasive aortic imaging

Non-invasive imaging of the aorta has undergone considerable advancements in recent times; largely driven by the technological advances in computed tomography (CT) and magnetic resonance imaging (MRI). This review article highlights these recent advancements and discusses the current role of different imaging tools in the management of aortic diseases.

Non-enhanced versus low-dose contrast-enhanced renal magnetic resonance angiography at 7 T: a feasibility study

Background Considering the currently reported association between a repetitive application and cumulative dosage of Gadolinium (Gd)-based contrast agents and Gd-deposition in brain tissue as well as the risk for the advent of nephrogenic systemic fibrosis (NSF), techniques allowing for a dose reduction become an important key aspect aside from non-enhanced magnetic resonance angiography (MRA) techniques. Thus, this study was focused on the reduction and/or complete omission of contrast agent for renal MRA at 7T. Purpose To evaluate the performance of time-of-flight MRA versus low-dose contrast-enhanced (CE) renal MRA at 7T. Material and Methods Ten healthy volunteers were examined on a 7T MR system comprising a TOF MRA and three-dimensional (3D) fast low angle shot spoiled gradient-echo sequence (FLASH) MRA after administration of one-quarter of clinical dose of gadobutrol. Qualitative image analysis was performed including overall image quality, artery delineation and presence of artifacts. Contrast ratio (CR), signal-to-noise ratio (SNR), and contrast-to-noise ratio (CNR) of the renal arteries were calculated. Results TOF MRA and low-CE MRA achieved comparable overall ratings, with slightly superior delineation of the main renal arteries in TOF MRA (TOF = 3.10 ± 0.75, low-CE = 2.95 ± 0.75). Segmental branches outside and inside the parenchyma were delineated significantly better on TOF MRA. Quantitative analysis demonstrated the superiority of TOF MRA, yielding higher scores for CR, SNR, and CNR. Conclusion The initial results of our study demonstrate the feasibility and comparable diagnostic performance of TOF and low-dose CE renal MRA at 7T.

Appropriate Minimal Dose of Gadobutrol for 3D Time-Resolved MRA of the Supra-Aortic Arteries: Comparison with Conventional Single-Phase High-Resolution 3D Contrast-Enhanced MRA

BACKGROUND AND PURPOSE

The development of nephrogenic systemic fibrosis and neural tissue deposition is gadolinium dose-dependent. The purpose of this study was to determine the appropriate minimal dose of gadobutrol with time-resolved MRA to assess supra-aortic arterial stenosis with contrast-enhanced MRA as a reference standard.

MATERIALS AND METHODS

Four hundred sixty-two consecutive patients underwent both standard-dose contrast-enhanced MRA and low-dose time-resolved MRA and were classified into 3 groups; group A (a constant dose of 1 mL for time-resolved MRA), group B (2 mL), or group C (3 mL). All studies were independently evaluated by 2 radiologists for image quality by using a 5-point scale (from 0 = failure to 4 = excellent), grading of arterial stenosis (0 = normal, 1 = mild [<30%], 2 = moderate [30%-69%], 3 = severe to occlusion [≥70%]), and signal-to-noise ratio.

RESULTS

The image quality of time-resolved MRA was similar to that of contrast-enhanced MRA in groups B and C, but it was inferior to contrast-enhanced MRA in group A. For the grading of arterial stenosis, there was an excellent correlation between contrast-enhanced MRA and time-resolved MRA (R = 0.957 for group A, R = 0.988 for group B, R = 0.991 for group C). The SNR of time-resolved MRA tended to be lower than that of contrast-enhanced MRA in groups A and B. However, SNR was higher for time-resolved MRA compared with contrast-enhanced MRA in group C.

CONCLUSIONS

Low-dose time-resolved MRA is feasible in the evaluation of supra-aortic stenosis and could be used as an alternative to contrast-enhanced MRA for a diagnostic technique in high-risk populations.

Contrast enhanced renal MR angiography at 7 Tesla: How much gadolinium do we need?

OBJECTIVES

To investigate whether a dose reduction of Gadobutrol for renal magnetic resonance angiography (MRA) at 7 Tesla (T) is feasible while preserving diagnostic image quality.

METHODS

Ten healthy volunteers were enrolled for a renal MRA on a 7T scanner. Fast low angle shot (FLASH) MRA data sets were obtained utilizing three different doses of Gadobutrol (0.1, 0.05 and 0.025mmol/kg body weight [BW]). Contrast ratios (CR) were measured in the aorta as well as in the intra- and extraparenchymal arteries compared to the psoas muscle. Qualitative analysis regarding the delineation of vessel structures was performed using a four-point-scale.

RESULTS

All doses of Gadobutrol allowed for a good delineation of the aorta and renal arteries. For the extra- and intraparenchymal segmental arteries higher values were observed for full and half dose in comparison to quarter dose. No significant difference was observed for full and half dose. A lower CR was observed for quarter compared to half dose (p<0.05) for the renal arteries.

CONCLUSIONS

While best results were observed for half and full dose, a dose reduction to 0.025mmol/kg BW is justifiable, maintaining a diagnostic image quality. This may be of high interest considering patients with renal impairment.

Comparison of extracranial artery stenosis and cerebral blood flow, assessed by quantitative magnetic resonance, using digital subtraction angiography as the reference standard

Extracranial arteriosclerosis usually indicates a high risk of ischemic stroke. In the past, a clinical decision following diagnosis was dependent on the percentage of vessel stenosis determined by an invasive technique. We aimed to develop a quantitative magnetic resonance (QMR) technique to evaluate artery structure and cerebral hemodynamics noninvasively.QMR and digital subtraction angiography (DSA) were performed in 67 patients with suspected cerebral vascular disease at our hospital. Accuracy, sensitivity, positive predictive values (PPVs), negative predictive values (NPVs), and Pearson correlation coefficient of QMR were calculated and compared for the detection and measurement of vascular stenoses using DSA as a gold standard. For patients with unilateral artery stenosis, quantitative cerebral blood flow (CBF) was measured by QMR in ipsilateral and contralateral hemispheres.Among 67 subjects (male 54, female 12), 201 stenoses were detected by QMR and DSA. QMR measuring the degree of stenosis and lesion length was in good correlation with the results obtained by DSA (r = 0.845, 0.721, respectively). As for artery stenosis, PPV and NPV of QMR were 89.55% and 95.71%, respectively. As for severe stenosis, sensitivity and specificity of QMR were 82.3% and 86.0% with DSA as a reference. For subjects with unilateral carotid stenosis, CBF in basal ganglia decreased significantly (P < 0.001) compared with the contralateral one in symptomatic and asymptomatic groups. For subjects with moderate stenosis (50-79%), CBF of temporal and basal ganglia was decreased compared with the contralateral ganglia. However, CBF in subjects with severe stenosis or occlusion in the basal ganglia was mildly elevated compared with the contralateral ganglia (P < 0.001).In our study, a good correlation was found between QMR and DSA when measuring artery stenosis and CBF. QMR may become an important method for measuring artery stenosis and cerebral hemodynamics in the future.

Cardiovascular MRI with ferumoxytol

The practice of contrast-enhanced magnetic resonance angiography (CEMRA) has changed significantly in the span of a decade. Concerns regarding gadolinium (Gd)-associated nephrogenic systemic fibrosis in those with severely impaired renal function spurred developments in low-dose CEMRA and non-contrast MRA as well as efforts to seek alternative MR contrast agents. Originally developed for MR imaging use, ferumoxytol (an ultra-small superparamagnetic iron oxide nanoparticle), is currently approved by the US Food and Drug Administration for the treatment of iron deficiency anaemia in adults with renal disease. Since its clinical availability in 2009, there has been rising interest in the scientific and clinical use of ferumoxytol as an MR contrast agent. The unique physicochemical and pharmacokinetic properties of ferumoxytol, including its long intravascular half-life and high r1 relaxivity, support a spectrum of MRI applications beyond the scope of Gd-based contrast agents. Moreover, whereas Gd is not found in biological systems, iron is essential for normal metabolism, and nutritional iron deficiency poses major public health challenges worldwide. Once the carbohydrate shell of ferumoxytol is degraded, the elemental iron at its core is incorporated into the reticuloendothelial system. These considerations position ferumoxytol as a potential game changer in the field of CEMRA and MRI. In this paper, we aim to summarise our experience with the cardiovascular applications of ferumoxytol and provide a brief synopsis of ongoing investigations on ferumoxytol-enhanced MR applications.

Introduction to Cardiovascular Magnetic Resonance: Technical Principles and Clinical Applications

Cardiovascular magnetic resonance (CMR) is a set of magnetic resonance imaging (MRI) techniques designed to assess cardiovascular morphology, ventricular function, myocardial perfusion, tissue characterization, flow quantification and coronary artery disease. Since MRI is a non-invasive tool and free of radiation, it is suitable for longitudinal monitoring of treatment effect and follow-up of disease progress. Compared to MRI of other body parts, CMR faces specific challenges from cardiac and respiratory motion. Therefore, CMR requires synchronous cardiac and respiratory gating or breath-holding techniques to overcome motion artifacts. This article will review the basic principles of MRI and introduce the CMR techniques that can be optimized for enhanced clinical assessment.

KEY WORDS

Cardiovascular MR • Coronary arteries • Flow quantification • Myocardial fibrosis • Myocardial perfusion • Myocardial scarring • Regional wall motion • Ventricular function.

Recent advances in 3D time-resolved contrast-enhanced MR angiography

Contrast-enhanced magnetic resonance angiography (CE-MRA) was first introduced for clinical studies approximately 20 years ago. Early work provided 3-4 mm spatial resolution with acquisition times in the 30-second range. Since that time there has been continuing effort to provide improved spatial resolution with reduced acquisition time, allowing high resolution 3D time-resolved studies. The purpose of this work is to describe how this has been accomplished. Specific technical enablers have been: improved gradients allowing reduced repetition times, improved k-space sampling and reconstruction methods, parallel acquisition, particularly in two directions, and improved and higher count receiver coil arrays. These have collectively made high-resolution time-resolved studies readily available for many anatomic regions. Depending on the application, ∼1 mm isotropic resolution is now possible with frame times of several seconds. Clinical applications of time-resolved CE-MRA are briefly reviewed.

Comparative analysis of fluorescent angiography, computed tomographic angiography and magnetic resonance angiography for planning autologous breast reconstruction

BACKGROUND

The high incidence of breast cancer and growing number of breast cancer patients undergoing mastectomy has led to breast reconstruction becoming an important part of holistic treatment for these patients. In planning autologous reconstructions, preoperative assessment of donor site microvascular anatomy with advanced imaging modalities has assisted in the appropriate selection of flap donor site, individual perforators, and lead to an overall improvement in flap outcomes. In this review, we compare the accuracy of fluorescent angiography, computed tomographic angiography (CTA), and magnetic resonance angiography (MRA) and their impact on clinical outcomes.

METHODS

A review of the published English literature dating from 1950 to 2015 using databases, such as PubMed, Medline, Web of Science, and EMBASE was undertaken.

RESULTS

Fluorescent angiography is technically limited by its inability to evaluate deep-lying perforators and hence, it has a minimal role in the preoperative setting. However, it may be useful intraoperatively in evaluating microvascular anastomotic patency and the mastectomy skin perfusion. CTA is currently widely considered the standard, due to its high accuracy and reliability. Multiple studies have demonstrated its ability to improve clinical outcomes, such as operative length and flap complications. However, concerns surrounding exposure to radiation and nephrotoxic contrast agents exist. MRA has been explored, however despite recent advances, the image quality of MRA is considered inferior to CTA.

CONCLUSIONS

Preoperative imaging is an essential component in planning autologous breast reconstruction. Fluorescent angiography presents minimal role as a preoperative imaging modality, but may be a useful intraoperative adjunct to assess the anastomosis and the mastectomy skin perfusion. Currently, CTA is the gold standard preoperatively. MRA has a role, particularly for women of younger age, iodine allergy, and renal impairment.

Combined low-dose contrast-enhanced MR angiography and perfusion for acute ischemic stroke at 3T: A more efficient stroke protocol

BACKGROUND AND PURPOSE

There is need to improve image acquisition speed for MR imaging in evaluation of patients with acute ischemic stroke. The purpose of this study was to evaluate the feasibility of a 3T MR stroke protocol that combines low-dose contrast-enhanced MRA and dynamic susceptibility contrast perfusion, without additional contrast.

METHODS

Thirty patients with acute stroke who underwent 3T MR imaging followed by DSA were retrospectively enrolled. TOF-MRA of the neck and brain and 3D contrast-enhanced MRA of the craniocervical arteries were obtained. A total of 0.1 mmol/kg of gadolinium was used for both contrast-enhanced MRA (0.05 mmol/kg) and dynamic susceptibility contrast perfusion (0.05 mmol/kg) (referred to as half-dose). An age-matched control stroke population underwent TOF-MRA and full-dose (0.1 mmol/kg) dynamic susceptibility contrast perfusion. The cervicocranial arteries were divided into 25 segments. Degree of arterial stenosis on contrast-enhanced MRA and TOF-MRA was compared with DSA. Time-to-maximum maps (>6 seconds) were evaluated for image quality and hypoperfusion. Quantitative analysis of arterial input function curves, SNR, and maximum T2* effects were compared between half- and full-dose groups.

RESULTS

The intermodality agreements (k) for arterial stenosis were 0.89 for DSA/contrast-enhanced MRA and 0.63 for DSA/TOF-MRA. Detection specificity of >50% arterial stenosis was lower for TOF-MRA (89%) versus contrast-enhanced MRA (97%) as the result of overestimation of 10% (39/410) of segments by TOF-MRA. The DWI-perfusion mismatch was identified in both groups with high interobserver agreement (r = 1). There was no significant difference between full width at half maximum of the arterial input function curves (P = .14) or the SNR values (0.6) between the half-dose and full-dose groups.

CONCLUSIONS

In patients with acute stroke, combined low-dose contrast-enhanced MRA and dynamic susceptibility contrast perfusion at 3T is feasible and results in significant scan time and contrast dose reductions.

Effectiveness of MR angiography for the primary diagnosis of acute pulmonary embolism: clinical outcomes at 3 months and 1 year

PURPOSE

To determine the effectiveness of MR angiography for pulmonary embolism (MRA-PE) in symptomatic patients.

MATERIALS AND METHODS

We retrospectively reviewed all patients whom were evaluated for possible pulmonary embolism (PE) using MRA-PE. A 3-month and 1-year from MRA-PE electronic medical record (EMR) review was performed. Evidence for venous thromboembolism (VTE) (or death from PE) within the year of follow-up was the outcome surrogate for this study.

RESULTS

There were 190 MRA-PE exams performed with 97.4% (185/190) of diagnostic quality. There were 148 patients (120 F: 28 M) that had both a diagnostic MRA-PE exam and 1 complete year of EMR follow-up. There were 167 patients (137 F: 30 M) with 3 months or greater follow-up. We found 83% (139/167) and 81% (120/148) MRA-PE exams negative for PE at 3 months and 1 year, respectively. Positive exams for PE were seen in 14% (23/167). During the 1-year follow-up period, five patients (false negative) were diagnosed with DVT (5/148 = 3.4 %), and one of these patients also experienced a non-life-threatening PE. The negative predictive value (NPV) for MRA-PE was 97% (92-99; 95% CI) at 3 months and 96% (90-98; 95% CI) with 1 year of follow-up.

CONCLUSION

The NPV of MRA-PE, when used for the primary diagnosis of pulmonary embolism in symptomatic patients, were found to be similar to the published values for CTA-PE. In addition, the technical success rate and safety of MRA-PE were excellent.

Safety and adverse effects during 24 hours after contrast-enhanced MRI with gadobenate dimeglumine (MultiHance) in children

BACKGROUND

Gadolinium-based MR contrast agents have long been considered safe for routine diagnostic imaging. However, the advent of nephrogenic systemic fibrosis (NSF) among certain patients with severe renal insufficiency has brought the issue of safety into question. Nowhere is safety of greater concern than among children who frequently require multiple contrast-enhanced MRI examinations over an extended period of time.

OBJECTIVE

To retrospectively evaluate the safety of gadobenate dimeglumine for contrast-enhanced (CE) MRI across a range of indications.

MATERIALS AND METHODS

Two hundred pediatric inpatients (age: 4 days to 15 years) underwent CE MRI as part of clinical routine. The children received a gadobenate dimeglumine dose of either 0.05 mmol/kg body weight (liver, abdominal imaging, musculoskeletal imaging, brain and other rare indications) or 0.1 mmol/kg bodyweight (cardiovascular imaging, MR-urography). Young (< 8 years) children with congenital heart disease were intubated and underwent MRA evaluation with controlled ventilation. Monitoring for adverse events was performed for at least 24 h after each gadobenate dimeglumine injection. Depending on clinical necessity, laboratory measurements and, in some cases, vital sign and ECG determinations were made before and after contrast injection. Safety was evaluated by age group, indication and dose administered.

RESULTS

No clinically adverse events were reported among children who had one MRI scan only or among children who had several examinations. There were no changes in creatinine or bilirubin levels even in very young children.

CONCLUSIONS

No adverse events were recorded during the first 24 h following administration of gadobenate dimeglumine in 200 children.

Multicenter, intraindividual comparison of single-dose gadobenate dimeglumine and double-dose gadopentetate dimeglumine for MR angiography of the supra-aortic arteries (the Supra-Aortic VALUE study)

BACKGROUND AND PURPOSE

Gadobenate dimeglumine has markedly higher R1 relaxivity compared to gadopentetate dimeglumine meaning that lower doses can be used to achieve similar contrast enhancement. Our aim was to prospectively compare single-dose gadobenate dimeglumine with double-dose gadopentetate dimeglumine for contrast-enhanced MRA of the supra-aortic vasculature.

MATERIALS AND METHODS

Forty-six patients (37 men, 9 women; mean age, 63.5±10.1 years) with known or suspected steno-occlusive disease of the supra-aortic vessels underwent 2 identical CE-MRA examinations at 1.5T. Contrast agents were administered in randomized order, with the 2-fold greater volume of gadopentetate dimeglumine injected at a 2 times faster rate. Image assessment was performed by 3 independent blinded readers for vessel anatomic delineation, detection/exclusion of pathology, and global preference. Diagnostic performance (sensitivity, specificity, accuracy, PPV, and NPV) for detection of ≥60% stenosis was determined for 39/46 patients who underwent preinterventional DSA. Data were analyzed by using the Wilcoxon signed-rank, McNemar, and Wald tests in terms of the noninferiority of single-dose gadobenate dimeglumine compared with double-dose gadopentetate dimeglumine. Quantitative enhancement (signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR)) was also compared.

RESULTS

All images were technically adequate. No differences (P=1.0) were noted by any reader for any qualitative parameter. All readers considered single-dose gadobenate dimeglumine and double-dose gadopentetate dimeglumine equivalent in at least 42/46 patients (91.3% three-reader agreement) for all parameters. Nonsignificant superiority for gadobenate dimeglumine was reported for all diagnostic performance indicators (sensitivity: 82.7%-88.5% versus 75.0%-80.8%; specificity: 96.4%-98.6% versus 94.6%-98.6%; accuracy: 94.6%-96.1% versus 92.4%-94.9%; PPV: 81.5%-91.5% versus 73.7%-90.7%; NPV: 96.8%-97.8% versus 95.4%-96.4%). No differences (P>.05) in quantitative enhancement were noted.

CONCLUSIONS

The image quality and diagnostic performance achieved with 0.1-mmol/kg gadobenate dimeglumine is at least equivalent to that achieved with 0.2-mmol/kg gadopentetate dimeglumine.

Current state-of-the-art 1.5 T and 3 T extracranial carotid contrast-enhanced magnetic resonance angiography

Recent advances in magnetic resonance (MR) hardware and software have improved the resolution and spatial coverage of head and neck first-pass contrast-enhanced (CE) MR angiography. Despite these improvements, high-quality submillimeter-resolution 1.5 T and 3 T carotid CE MR angiography is not consistently available in the general radiology practice. This article reviews the important imaging parameters and potential pitfalls that affect carotid CE MR angiography image quality, and the dose and timing of the gadolinium-based contrast agent, and summarizes vendor-specific protocols for high-quality submillimeter-resolution carotid CE MR angiography at 1.5 and 3 T.

Low dose CE-MRA

Over the last decade, three-dimensional contrast-enhanced magnetic resonance angiography (CE-MRA) has emerged as a widely accepted and powerful technique for diagnostic assessment of almost all vascular territories. Its non-invasive nature and lack of ionizing radiation, its potential to cover a large field of view and the safety of gadolinium-based contrast agents make CE-MRA an appealing alternative to digital subtraction angiography (DSA) or computed tomography angiography (CTA). However, recent reports linking high dose gadolinium-based contrast agents to the development of nephrogenic systemic fibrosis [1-3] have raised concerns over the safety of CE-MRA. As a result, many investigators have focused attention on gadolinium dose reduction strategies [4,5]. This article reviews existing state-of-the-art 3D CE-MRA strategies to reduce contrast dose and summarizes current applications and clinical experience to date. It also highlights evolving techniques, which the authors feel are likely to enhance the future impact of CE-MRA.

Magnetic resonance angiography: current status and future directions

With recent improvement in hardware and software techniques, magnetic resonance angiography (MRA) has undergone significant changes in technique and approach. The advent of 3.0 T magnets has allowed reduction in exogenous contrast dose without compromising overall image quality. The use of novel intravascular contrast agents substantially increases the image windows and decreases contrast dose. Additionally, the lower risk and cost in non-contrast enhanced (NCE) MRA has sparked renewed interest in these methods. This article discusses the current state of both contrast-enhanced (CE) and NCE-MRA. New CE-MRA methods take advantage of dose reduction at 3.0 T, novel contrast agents, and parallel imaging methods. The risks of gadolinium-based contrast media, and the NCE-MRA methods of time-of-flight, steady-state free precession, and phase contrast are discussed.

Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols

PURPOSE

To retrospectively determine the incidence of nephrogenic systemic fibrosis (NSF) in patients on dialysis administered either a lower dose high-relaxivity linear gadolinium-chelate, gadobenate dimeglumine (MultiHance, MH), compared to a standard dose linear gadolinium chelate, gadodiamide (Omniscan, OM).

MATERIALS AND METHODS

This study was Health Insurance Portability and Accountability Act (HIPAA)-compliant and Institutional Review Board (IRB)-approved. As per institution standardized contrast-enhanced magnetic resonance imaging (MRI) protocols, patients on dialysis were imaged using either MH, between 2/2007 to 9/2008, or OM between 10/2003 and 1/2007. Rates of NSF were compared using 95% score-based confidence intervals (CI). The Wilcoxon rank sum test was used to test similarity/difference between contrast doses given to each patient group.

RESULTS

Overall, 312 patients on dialysis received OM and eight (2.6%) developed NSF (95% CI: 1.30%-4.98%). In all, 784 patients on dialysis received MH at a mean cumulative dose of 0.11 mmol/kg (0.05-0.75 mmol/kg) and no cases of NSF were identified (upper 95% confidence bound of 0.45%). The mean cumulative dose of OM was 0.16 mmol/kg (0.1-0.9 mmol/kg) for all patients and 0.28 mmol/kg (0.1-0.8 mmol/kg) for the patients with NSF. The median OM dose was greater in patients who developed NSF (P = 0.03), and was greater than the median MH dose (P < 0.005).

CONCLUSION

NSF incidence in at-risk patients receiving contrast-enhanced MRI can be reduced after changing contrast administration protocols that includes changing the type and dose of contrast agent.

High-resolution cartilage imaging of the knee at 3T: basic evaluation of modern isotropic 3D MR-sequences

PURPOSE

To evaluate qualitative and quantitative image quality parameters of isotropic three-dimensional (3D) cartilage-imaging magnetic resonance (MR)-sequences at 3T.

MATERIALS AND METHODS

The knees of 10 healthy volunteers (mean age, 24.4±5.6 years) were scanned at a 3T MR scanner with water-excited 3D Fast-Low Angle Shot (FLASH), True Fast Imaging with Steady-state Precession (TrueFISP), Sampling Perfection with Application-optimized Contrast using different flip-angle Evolutions (SPACE) as well as conventional and two individually weighted Double-Echo Steady-State (DESS) sequences. The MR images were evaluated qualitatively and quantitatively (signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), SNR efficiency, CNR efficiency). Quantitative parameters were compared by means of a Tukey-test and sequences were ranked according to SNR/CNR, SNR/CNR efficiency and qualitative image grading.

RESULTS

The highest SNR was measured for SPACE (34.0±5.6), the highest CNR/CNR efficiency (cartilage/fluid) for the individually weighted DESS (46.9±18.0/2.18±0.84). SPACE, individually weighted and conventional DESS were ranked best with respect to SNR/CNR and SNR/CNR efficiency. The DESS sequences also performed best in the qualitative evaluation. TrueFISP performed worse, FLASH worst. The individually weighted DESS sequences were generally better than the conventional DESS with the significant increase of cartilage-fluid contrast (46.9±18.0/31.9±11.4 versus 22.0±7.3) as main advantage.

CONCLUSION

Individually weighted DESS is the most promising candidate; all tested sequences performed better than FLASH.

Ten-year experience with nephrogenic systemic fibrosis: case-control analysis of risk factors

OBJECTIVES

To analyze all cases of nephrogenic systemic fibrosis (NSF) at our institution and to compare them with controls.

METHODS

After the institutional review board approval, 13 biopsy-proven NSF cases were identified. Ten cases had complete records and were compared in a case-control format with 10 age- and sex-matched, dialysis-dependent controls. Analyzed risk factors included single and cumulative gadolinium dose, medication and transplant history, and serum electrolytes at the time of gadolinium exposure.

RESULTS

There were 1.9% of dialysis-dependent, gadolinium-exposed patients who developed NSF. There was no difference in gadolinium dose, transplant history, or serum electrolytes. Seven of 10 cases and 3 of 10 controls were treated with erythropoietin (P = 0.13). At the time of NSF diagnosis, 7 of 10 cases were on immunosuppressive therapy. Two of 7 cases developed NSF only after immunosuppressive therapy was initiated. Two of 10 controls were on immunosuppressive therapy (P = 0.06).

CONCLUSIONS

All cases of NSF occurred in dialysis-dependent, gadolinium-exposed patients. Associations between immunosuppressive and erythropoietin therapies and NSF need further investigation.

Magnetic resonance angiography of the extracranial carotid system

OBJECTIVES

To discuss the role of magnetic resonance angiography (MRA) in the evaluation of the extracranial carotid system with an emphasis on atherosclerosis and to briefly address the role of magnetic resonance imaging in imaging of carotid atherosclerotic plaque.

METHODS

Literature and institutional review.

DISCUSSION

The North American Symptomatic Carotid Endarterectomy Trial and European Carotid Surgery Trial studies have emphasized the importance of recognition and treatment of carotid stenosis in the prevention of ischemic stroke. Magnetic resonance angiography is a viable tool in the screening and quantification of this entity. Both time of flight and contrast-enhanced MRA techniques are available for clinical use, each with distinct advantages and limitations. A thorough understanding of these is vital for correct performance and interpretation of these studies. Plaque imaging with magnetic resonance imaging offers new insights into the pathophysiology of the atherosclerotic process and may be used in the future to monitor response to lipid-lowering drug therapy.

CONCLUSION

Magnetic resonance angiography is a robust imaging technique for evaluation of the extracranial carotid circulation. The radiologist must be aware of the advantages and limitations of the different techniques available. Contrast-enhanced MRA is now the most widely performed technique. It can be used to replace digital subtraction angiography in the evaluation of carotid stenosis in most clinical settings.

Ultra-low-dose, time-resolved contrast-enhanced magnetic resonance angiography of the carotid arteries at 3.0 tesla

PURPOSE

To determine whether time-resolved magnetic resonance angiography (TR-MRA) with ultra-low-dose gadolinium chelate (1.5-3.0 mL) can reliably detect or rule out hemodynamically significant disease in the carotid-vertebral artery territory.

MATERIALS AND METHODS

Hundred consecutive patients (62 women, 38 men, mean age = 56.6 years) underwent both TR-MRA and standard high-resolution contrast-enhanced magnetic resonance angiography (CE-MRA), having been randomized to 1 of 2 groups; group A receiving a contrast dose of 1.5 mL for TR-MRA and group B receiving 3.0 mL. For scoring purposes the arterial system was divided into 21 segments. All TR-MRA and CE-MRA studies were blindly assessed by 2 radiologists for overall image quality, segmental arterial visualization, grading of arterial stenosis/occlusion, and incidence and severity of artifact. TR-MRA findings were directly compared with those of the corresponding CE-MRA examinations.

RESULTS

Group A TR-MRA studies were of significantly inferior overall image quality compared with those of the corresponding CE-MRA examinations (P = 0.01 for both observers). In group B, overall image quality was similar for TR-MRA and single-phase CE-MRA examinations. On a segmental basis, a higher number of "insufficient quality" segments were identified in group A TR-MRA studies than in group B. A similar reduction in the incidence of artifacts was observed for group B relative to group A TR-MRA studies. Both groups A and B TR-MRA studies were of high specificity, negative predictive values, and accuracy (>97%).

CONCLUSION

Ultra-low dose TR-MRA may be performed with 3 mL of gadolinium chelate with preservation of overall image quality and arterial segmental visualization relative to single phase CE-MRA, whereas a 1.5 mL contrast dose is associated with more suboptimal studies. Nonetheless, even at doses as low as 1.5 mL, TR-MRA can exclude arterial stenosis or occlusion.